Gemfibrozil

Gemfibrozil

Clinical data
Trade names	Lopid
AHFS/Drugs.com	Monograph
MedlinePlus	a686002
Pregnancy category	Category C
Routes of administration	Oral
ATC code	C10AB04 (WHO)
Legal status
Legal status	By Prescription
Pharmacokinetic data
Bioavailability	Close to 100%
Protein binding	95%
Metabolism	Hepatic (CYP3A4)
Biological half-life	1.5 hours
Excretion	Renal 94% Feces 6%
Identifiers
IUPAC name 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
CAS Number	25812-30-0 Y
PubChem CID	3463
IUPHAR/BPS	3439
DrugBank	DB01241 Y
ChemSpider	3345 Y
UNII	Q8X02027X3
KEGG	D00334 Y
ChEBI	CHEBI:5296 Y
ChEMBL	CHEMBL457 Y
ECHA InfoCard	100.042.968
Chemical and physical data
Formula	C15H22O3
Molar mass	250.333 g/mol
3D model (Jmol)	Interactive image
Melting point	61 to 63 °C (142 to 145 °F)
SMILES O=C(O)C(C)(C)CCCOc1cc(ccc1C)C
InChI InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17) Y Key:HEMJJKBWTPKOJG-UHFFFAOYSA-N Y

Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.

Gemfibrozil was selected from a series of related compounds synthesized in the laboratories of the American company Parke Davis in the late 1970s. It came from research for compounds that lower plasma lipid levels in humans and in animals.

Gemfibrozil has been detected in biosolids (the solids remaining after wastewater treatment) at concentrations up to 2650 ng/g wet weight. This indicates that it survives the wastewater treatment process.